Compare GLAD & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLAD | BWAY |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | Israel |
| Employees | 65 | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.7M | 450.8M |
| IPO Year | N/A | N/A |
| Metric | GLAD | BWAY |
|---|---|---|
| Price | $18.20 | $23.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $22.33 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 209.7K | 81.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.62% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.46 | $314.08 |
| Revenue Next Year | $8.40 | $23.37 |
| P/E Ratio | ★ $11.70 | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.91 | $7.84 |
| 52 Week High | $29.50 | $26.63 |
| Indicator | GLAD | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 48.74 |
| Support Level | N/A | $21.93 |
| Resistance Level | $21.54 | $25.71 |
| Average True Range (ATR) | 0.44 | 1.36 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 25.74 | 30.62 |
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.